Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $2.41 USD
Change Today 0.00 / 0.00%
Volume 87.0K
TRGT On Other Exchanges
Symbol
Exchange
Berlin
NASDAQ GS
As of 8:10 PM 04/17/15 All times are local (Market data is delayed by at least 15 minutes).

targacept inc (TRGT) Snapshot

Open
$2.40
Previous Close
$2.41
Day High
$2.43
Day Low
$2.34
52 Week High
07/3/14 - $4.68
52 Week Low
04/9/15 - $2.18
Market Cap
81.4M
Average Volume 10 Days
133.5K
EPS TTM
$-0.86
Shares Outstanding
33.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for TARGACEPT INC (TRGT)

Related News

No related news articles were found.

targacept inc (TRGT) Related Businessweek News

No Related Businessweek News Found

targacept inc (TRGT) Details

Targacept, Inc., a biopharmaceutical company, engages in the development of neuronal nicotinic receptors (NNR) therapeutics for the treatment of nervous system and gastrointestinal/genitourinary diseases and disorders. Its product candidates include TC-6499 for the treatment of diabetic gastroparesis; and TC-5619 and TC-6987, which are novel small molecules that are selective for the a7 NNR. The company was founded in 1997 and is based in Winston-Salem, North Carolina.

19 Employees
Last Reported Date: 03/16/15
Founded in 1997

targacept inc (TRGT) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $644.5K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $294.0K
Senior Vice President, General Counsel and Se...
Total Annual Compensation: $385.7K
Vice President of Business Development
Total Annual Compensation: $238.9K
Compensation as of Fiscal Year 2014.

targacept inc (TRGT) Key Developments

Targacept Announces Negative Top-Line Results from Exploratory Study of Tc-6499 in Diabetic Gastroparesis

Targacept, Inc. announced top-line results from a Phase 1/2 exploratory study of TC-6499 as a treatment for diabetic gastroparesis, a chronic disorder that slows or stops the passage of food from the stomach to the small intestine. In the trial, TC-6499 did not meet the primary endpoint of the study, change in gastric emptying half-time (BT_t1/2), as measured by a carbon (13C) labeled gastric emptying breath test, relative to placebo.

Targacept, Inc. Terminates Employment of Steven M. Toler, Vice President, Clinical Pharmaceutical Sciences, Effective March 31, 2015

On March 11, 2015, Targacept, Inc. terminated the employment of Steven M. Toler, PharmD., Ph.D., Vice President, Clinical Pharmaceutical Sciences of the Company, effective March 31, 2015.

Catalyst Biosciences, Inc., Targacept, Inc. - M&A Call

To discuss proposed merger between the two companies

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TRGT:US $2.41 USD 0.00

TRGT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Amorfix Life Sciences Ltd C$0.05 CAD -0.005
Eli Lilly & Co $72.47 USD -1.02
Novartis AG SFr.97.20 CHF -1.85
Pfizer Inc $35.04 USD -0.15
View Industry Companies
 

Industry Analysis

TRGT

Industry Average

Valuation TRGT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 296.2x
Price/Book 0.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TARGACEPT INC, please visit www.targacept.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.